March 25, 2007 -- Last week, biotech won back some of the ground lost in its 6% drop of two weeks ago. Over the five sessions, the Centient Biotech 200™ rose 95 points to 3897, a substantial increase of 2.5%. Breadth was solidly positive. No new IPOs last week, but device maker SenoRx is expected this coming week. Osiris moved higher in advance of good clinical results from its stem cell treatment for heart attacks; Acadia doubled on positive news from a schizophrenia drug; ImClone rose on bad news on a competing drug from Amgen; Adams Respiratory moved higher after settling a patent case over its decongestant Mucinex; Ciphergen climbed on prospects for its ovarian cancer test; and Dendreon traded higher in advance of a showdown with an FDA advisory panel over cancer vaccine Provenge. More details...
